SUO 2018: Debate: Enucleo-Resection vs. Wedge Resection for Partial Nephrectomy in 4 cm tumors - CON

Phoenix, Arizona (UroToday.com) Dr. Finelli summarized several key points on why enucleation should not be used as the standard of care for partial nephrectomy. He started his talk presenting a case of a 56 year old man with morbid obesity and no family history of cancer, who was found to have a left renal mass.

SUO 2018: Hereditary Kidney Cancer and Genetic Testing

Phoenix, Arizona (UroToday.com) Dr. Maria Carlo gave a brief overview of the more common and less common renal hereditary cancer syndromes and some guidelines on when should patients be referred for genetic testing. Figure 1 demonstrates the prevalence of germline mutations in renal cell carcinoma (RCC) cases in the cancer genome atlas (TCGA).

SUO 2018: Long-term Outcomes of Active Surveillance for Prostate Cancer – The Memorial Sloan Kettering Cancer Center Experience

Phoenix, Arizona (UroToday.com) Dr. Carlsson presented the Memorial Sloan Kettering Cancer Center experience with active surveillance over a long-term follow-up. Most patients with low-risk prostate cancer end up getting treatment, however, the rate of active surveillance in the US over the last years has increased significantly to almost 50% of low-risk patients. Interestingly, the rate of active surveillance in Sweden is extremely high for low-risk patients (~80%) and for intermediate risk patients as well (~20%).

SUO 2018: Post-Operative Opioid Prescribing in Urology: Are We Contributing to The National Crisis?

Phoenix, Arizona (UroToday.com) Dr. Hackler presented on postoperative opioid prescribing in urology. This topic has gained a lot of traction worldwide.

SUO 2018: Cytoreductive Nephrectomy Is No Longer Standard of Care in Patients with Metastatic Renal Cell Carcinoma

Phoenix, Arizona (UroToday.com) Dr. Tannir gave a discussion on why cytoreductive nephrectomy should not be the standard of care in metastatic renal cell carcinoma (RCC). Dr. Tannir believes that cytoreductive nephrectomy is for intermediate risk patients only. In the cytokine era cytoreductive nephrectomy was shown to prolong overall survival by 6-7 months (1,2). The benefit of cytoreductive nephrectomy is inversely associated with the efficacy of systemic therapies.

SUO 2018: An Oncolytic Adenovirus, for BCG-unresponsive Non-muscle-invasive Bladder Cancer (NMIBC): 18-month Follow-up from a Multicenter Phase II Trial

Phoenix, Arizona (UroToday.com) Dr. Packiam presented his work from Mayo clinic, Rochester, on CG0070, an oncolytic adenovirus, for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC): Final 18-month interim results from a multicenter phase 2 trial.

SUO 2018: Surgical Perspective on Management for Hereditary Kidney Cancer

Phoenix, Arizona (UroToday.com) Dr. Shuch gave a great talk on the surgical management of hereditary kidney cancer. Unfortunately, to date, there is no level 1 evidence regarding the treatment of hereditary renal cell carcinoma (RCC). A high volume of hereditary RCC cases treated with surgical management is a unique experience shared at several high-volume hospital centers. The data gathered on the surgical management of these cases is at best described in case reports, learnt through trial and error.
E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe